Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 11/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | PER2 | O15055 | 1/20 | 0.30 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.30 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13623335 | 1.00 | SLC6A4 (0.34) | SLC6A4SLC6A2SLC6A3KMT2AMEN1 | |
| SCHEMBL13622767 | 0.84 | SLC6A4 (0.34) | SLC6A4SLC6A2SLC6A3KCNH2AGTR2 | |
| SCHEMBL8003405 | 0.82 | KMT2A (0.43) | SLC6A4SLC6A2SLC6A3KMT2AMEN1 | |
| SCHEMBL2091299 | 0.73 | KMT2A (0.50) | KMT2AMEN1ALDH1A1POLBTSHR | |
| SCHEMBL2093629 | 0.71 | KMT2A (0.49) | KMT2AMEN1ALDH1A1POLBTSHR | |
| SCHEMBL22797998 | 0.71 | TACR1 (0.33) | SLC6A4SLC6A2SLC6A3KMT2AMEN1 | |
| SCHEMBL1088743 | 0.69 | ALDH1A1 (0.40) | SLC6A4SLC6A2KMT2AMEN1KCNH2 | |
| SCHEMBL25930907 | 0.68 | SLC6A4 (0.33) | SLC6A4SLC6A2SLC6A3KCNH2TSHR | |
| SCHEMBL13622772 | 0.68 | SLC6A4 (0.31) | SLC6A4 | |
| SCHEMBL1309394 | 0.66 | SLC6A4 (0.43) | SLC6A4SLC6A2SLC6A3KCNH2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275574-A1 | NOVEL COMPOUNDS-300 | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275574-A1 | NOVEL COMPOUNDS-300 | CACNA1A, SCN10A, OPRM1 | SLC6A4 986/4885SLC6A2 1415/4885SLC6A3 1282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.